Mental Health DailyResearch. Evidence. Perspective.Published research on gabapentin.
A 2026 scoping review screened 956 systematic reviews/guidelines and 604 original studies on cancer-survivor neuropathic pain, but only 11 pharmacological, 2 psychological, and 3 exercise st…
Read articleA 210-person randomized assessor-blinded trial found that adding weekly Hegu-point catgut embedding to gabapentin improved 4-week postherpetic-neuralgia response from 80.00% to 92.38%; compa…
Read articleA 2026 Taiwanese case series reported VAS pain drops in all 3 adults treated with pregabalin for type I complex regional pain syndrome: 9 to 5, 2 to 1, and 6 to 3 after doses of 75-150 mg/da…
Read articleLyrica (pregabalin) and Neurontin (gabapentin) are both classified as “gabapentinoids” (i.e. α2δ ligands). As gabapentinoids, Lyrica (pregabalin) and Neurontin (gabapentin) are chemical anal…
Read articleGabapentin, sold under the brand name “Neurontin,” is a drug that was first approved by the United States FDA in 1993 as an adjunct treatment for partial seizures in adults. Thereafter, gaba…
Read articleGabapentin is rumored to have been synthesized by chemists in the 1970s in attempt to develop an antispasmodic agent. After its synthesis, rights to gabapentin were acquired by Parke-Davis (…
Read articleGabapentin (brand name “Neurontin”) is a drug initially approved by the FDA in 1993 as an adjunct treatment for partial seizures, and 11 years later in 2004, received approval for the treatm…
Read article
